Ozempic face: what causes it, who gets it, and what helps in 2026

What 'Ozempic face' actually is

The term refers to a sunken, gaunt facial appearance — flatter cheeks, more visible orbital hollows, slacker jawline — observed in some people on GLP-1 medications. It became a dermatology vernacular term around 2022 as off-label use of GLP-1s for weight loss accelerated. Despite the name, it is not listed as a side effect in any GLP-1 FDA label and is not caused by the drug directly.

What's happening: the face loses subcutaneous fat the same way the rest of the body does. The face has dedicated fat pads (malar, buccal, deep medial cheek) that contribute to its 'full' youthful contour. Lose those quickly and the overlying skin — which remodels slower than fat — temporarily looks loose. This mismatch is the visual phenomenon. It would happen with any rapid weight loss method, including bariatric surgery or severe caloric restriction.

Who's most at risk

Three factors meaningfully predict who develops a visible Ozempic-face look: age (>40, where dermal collagen and elastin are already declining), starting BMI (lower starting BMI means less fat to spare), and rate of weight loss (>1% of body weight per week consistently). Genetic skin elasticity also matters.

The cosmetic effect is largely independent of which GLP-1 you take. Wegovy, Zepbound, and Mounjaro all produce similar facial-volume change for similar percentage weight loss. Higher-efficacy drugs (tirzepatide, retatrutide) just allow faster loss, which compresses the timeline during which the mismatch is most visible.

What helps (evidence-graded)

Strongest evidence: slow your rate of loss. Aiming for 0.5-0.75% of body weight per week (rather than 1-2%) gives skin and connective tissue time to remodel. This often means staying on a lower maintenance dose longer or pausing dose escalation. Discuss with your prescriber.

Strong evidence: preserve lean mass with 1.2-1.6 g protein per kg of body weight daily and resistance training at least twice weekly. Muscle under the facial bone structure (masseter, temporalis) contributes to fullness.

Moderate evidence: dermatology-led intervention. Hyaluronic acid filler can replace deep medial cheek and tear-trough volume (effect lasts 9-18 months). Microfocused ultrasound (Ultherapy) and radiofrequency (Morpheus8, Sofwave) tighten skin via collagen remodeling. Polylactic acid (Sculptra) and calcium hydroxylapatite (Radiesse) provide longer-lasting volume via collagen stimulation. Costs $600-$4,500 per session.

Weak evidence: topical retinoids, peptides, sunscreen. They help dermal quality in general but don't specifically reverse Ozempic face. Sunscreen prevents the photoaging that compounds the look.

No evidence: supplements marketed to 'restore Ozempic face' (collagen powder, biotin, herbal blends). Research doesn't support meaningful facial-volume restoration from oral supplementation here.

What doesn't help (a may hurt)

Stopping GLP-1 prematurely. Most people who discontinue without a maintenance plan regain 50-70% of lost weight within 12 months. The face fills back in — but the metabolic and cardiovascular benefits reverse too. The right approach is dose adjustment and slower loss, not abandonment.

Aggressive facial fat grafting during active loss. Several plastic surgery societies recommend waiting until weight has stabilized for at least 6 months before structural cosmetic work, because grafted fat in an actively-losing patient can be lost like native fat.

Online sellers of compounded peptides claiming to 'rebuild facial fat'. No FDA-approved peptide for site-specific fat regeneration exists. Many products are unregulated and unsafe.